New diabetes pill shows Real-World promise in finnish study
NCT ID NCT05443191
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 34 times
Summary
This study followed 50 adults with type 2 diabetes in Finland who were already prescribed oral semaglutide (Rybelsus) by their doctor. Researchers tracked changes in blood sugar (HbA1c) and body weight over 8-10 months. Participants also filled out a questionnaire about how they took their medication. The goal was to see how well the pill works in everyday life, not in a controlled lab setting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Aava Lääkärikeskus Kamppi
Helsinki, 00100, Finland
-
Master Centre for Finland
Helsinki, Finland, 00100, Finland
-
Master centre for France_Paris La défense cedex
Paris, La Défense, cedex, France
Conditions
Explore the condition pages connected to this study.